SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Despite weight loss and glycemic control, experts caution that type 2 diabetes remission is not a cure and that pancreatic ...

The best-selling author and podcaster on how to preserve robust physical, cognitive and emotional health, and how Medicine ...

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

At the foundation of healthspan medicine are the pillars of health. These are easily understood through four simple verbs: ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

SGLT2 inhibitors were associated with greater reduction in MACE risk among older adults than younger adults with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a greater ...

Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

Researchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a ...

The following is a summary of “Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial,” published in the February 2025 issue of Nephrology Dialysis ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...